Efficacy of systemic corticosteroids in refractory asthmatics showing no bronchial reversibility with high-dose inhaled corticosteroids or β2 agonist inhalation Source: Annual Congress 2010 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2010
Risks of pneumonia in asthmatic patients taking inhaled corticosteroids Source: Annual Congress 2010 - Management of airway disease Year: 2010
Adrenal insufficiency in asthma treated with high/low systemic corticosteroids in the past and in those who sucessfully discontinued systemic corticosteroids after treatment with omalizmab. Source: International Congress 2017 – Management of asthma in different situations Year: 2017
High pulse dose steroids in Severe COVID-19 pneumonitis refractory hypoxemia to dexamethasone Source: Virtual Congress 2021 – Highlights in COVID-19 diagnosis and treatment Year: 2021
High-dose inhalation corticosteroids in conjunction with plasmapheresis in the treatment of patients with acute variant of exogenic allergic alveolitis (EAA) Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura Year: 2012
Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma Source: Eur Respir J, 55 (1) 1901147; 10.1183/13993003.01147-2019 Year: 2020
Nebulizer therapy with budesonide in addition to systemic corticosteroids in acute severe asthma Source: Eur Respir J 2004; 24: Suppl. 48, 541s Year: 2004
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids Source: Breathe 2010; 6: 365 Year: 2010
Improvement in SARS-CoV2 lung interstitial injuries with systemic corticosteroid treatment Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends Year: 2021
Inhaled corticosteroids in the treatment of acute asthma Source: Eur Respir J 2002; 20: Suppl. 38, 305s Year: 2002
Efficacy and safety of high-dose inhaled corticosteroids therapy in children with asthma Source: Annual Congress 2010 - Allergy and risk factors in paediatrics Year: 2010
Low risk of adrenal dysfunction in children with severe asthma treated with high-dose inhaled glucocorticoids Source: Eur Respir J 2005; 26: Suppl. 49, 161s Year: 2005
Long-term outcome of infants treated for acute bronchiolitis with inhaled steroids Source: Eur Respir J 2001; 18: Suppl. 33, 169s Year: 2001
Low-dose inhaled and nasal corticosteroid use and the risk of cataracts Source: Eur Respir J 2006; 27: 1168-1174 Year: 2006
An economic evaluation of adding inhaled corticosteroids to systemic corticosteroids for treating acute asthma exacerbations Source: International Congress 2019 – Severe acute asthma and troublesome wheezing Year: 2019
Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis Source: ERJ Open Res, 3 (3) 00016-2017; 10.1183/23120541.00016-2017 Year: 2017
Mechanisms of systemic side effects of inhaled steroids Source: Eur Respir J 2004; 24: Suppl. 48, 347s Year: 2004
Incidence of oropharyngeal candidiasis during treatment with high doses of inhaled corticosteroids Source: Eur Respir J 2002; 20: Suppl. 38, 111s Year: 2002
Comparison of inhaled corticosteroid combined with theophylline and double-dose inhaled corticosteroid in moderate-severe persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 127s Year: 2004
Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis Source: Eur Respir J, 54 (1) 1801896; 10.1183/13993003.01896-2018 Year: 2019